The C Allele of ATM rs 11212617 Does Not Associate With Metformin Response in the Diabetes Prevention Program

• Autores: Jose C. Florez, Kathleen A. Jablonski, Andrew Taylor, Kieren Mather, Edward Horton, Neil H. White, Elizabeth Barrett-Connor, William C. Knowler, Alan R. Shuldiner, Toni I. Pollin
• Localización: Diabetes care, ISSN-e 0149-5992, Vol. 35, Nº. 9, 2012, págs. 1864-1867
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The C allele at the rs11212617 polymorphism in the ataxia-telangiectasia-mutated (ATM) gene has been associated with greater clinical response to metformin in people with type 2 diabetes. We tested whether this variant modified the effect of metformin in the Diabetes Prevention Program (DPP), in which metformin reduced diabetes incidence by 31% in volunteers with impaired glucose tolerance. We genotyped rs11212617 in 2,994 DPP participants and analyzed its effects on diabetes incidence and related traits. Contrary to expectations, C carriers enjoyed no preventive advantage on metformin; their hazard ratio, compared with A carriers, was 1.17 ([95% CI 0.96-1.42], P = 0.13) under metformin. There were no significant differences by genotype in metformin's effects on insulin sensitivity, fasting glucose, glycated hemoglobin, or disposition index. The reported association of rsl 1212617 with metformin response was not confirmed for diabetes prevention or for effects on relevant physiologic parameters in the DPP.